Guardant Health CTO converts awards into 8,033 shares

Q: How many GH shares did Darya Chudova acquire through RSU vesting?

The reported transactions converted 8,033 restricted stock units into common shares for Darya Chudova, Guardant Health’s Chief Technology Officer, on October 1, 2026. The transactions involved four restricted stock unit awards.

Q: How many GH shares were withheld for taxes?

The company retained 4,320 common shares to meet the award-holder’s tax withholding obligations on October 1, 2026. The shares were reported at $174.75 per share, and the amount retained did not exceed the tax liability.

The Chief Technology Officer’s four restricted stock unit awards converted into common shares, with 4,320 shares retained for tax withholding.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Technology Officer Darya Chudova reported conversion of 8,033 restricted stock units into common stock on October 1, 2026. On the same date, the company retained 4,320 shares to meet the award-holder’s tax withholding obligations, at a reported price of $174.75 per share. The filing states the amount retained did not exceed the tax liability.

Insider Trade Summary

8,033 shares exercised/converted

Exercise 9 txns

Insider Chudova Darya

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^{F2, F3}	1,340	$0.00	$0.00
Exercise	Restricted Stock Units ^{F4, F3}	1,668	$0.00	$0.00
Exercise	Restricted Stock Units ^{F5, F3}	3,324	$0.00	$0.00
Exercise	Restricted Stock Units ^{F6, F3}	1,701	$0.00	$0.00
Exercise	Common Stock	1,340	$0.00	$0.00
Exercise	Common Stock	1,668	$0.00	$0.00
Exercise	Common Stock	3,324	$0.00	$0.00
Exercise	Common Stock	1,701	$0.00	$0.00
Tax Withholding	Common Stock ^F1	4,320	$174.75	$755K

Holdings After Transaction: Restricted Stock Units — 23,498 contracts (Direct); Common Stock — 74,348 shares (Direct)

Footnotes (6)

F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2. This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
F3. Not applicable for Restricted Stock Units.
F4. This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F5. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Key Figures

Restricted stock units converted: 8,033 restricted stock units Shares retained for tax withholding: 4,320 shares Reported price per share: $174.75 per share

3 metrics

Restricted stock units converted 8,033 restricted stock units October 1, 2026

Shares retained for tax withholding 4,320 shares October 1, 2026

Reported price per share $174.75 per share Tax withholding transaction on October 1, 2026

Key Terms

Restricted Stock Units, tax withholding obligations, vested in equal quarterly installments

3 terms

Restricted Stock Units financial

"restricted stock unit award granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"meet the tax withholding obligations of the award-holder"

vested in equal quarterly installments financial

"vested in equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GH shares did Darya Chudova acquire through RSU vesting?

The reported transactions converted 8,033 restricted stock units into common shares for Darya Chudova, Guardant Health’s Chief Technology Officer, on October 1, 2026. The transactions involved four restricted stock unit awards.

How many GH shares were withheld for taxes?

The company retained 4,320 common shares to meet the award-holder’s tax withholding obligations on October 1, 2026. The shares were reported at $174.75 per share, and the amount retained did not exceed the tax liability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 05:00 PM Accepted by SEC EDGAR 10/02/2026 - 04:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudova Darya

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		1,340	A	$0	71,975	D
Common Stock	10/01/2026		M		1,668	A	$0	73,643	D
Common Stock	10/01/2026		M		3,324	A	$0	76,967	D
Common Stock	10/01/2026		M		1,701	A	$0	78,668	D
Common Stock	10/01/2026		F		4,320⁽¹⁾	D	$174.75	74,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	10/01/2026		M			1,340	⁽²⁾	⁽³⁾	Common Stock	1,340	$0	0	D
Restricted Stock Units	$0	10/01/2026		M			1,668	⁽⁴⁾	⁽³⁾	Common Stock	1,668	$0	0	D
Restricted Stock Units	$0	10/01/2026		M			3,324	⁽⁵⁾	⁽³⁾	Common Stock	3,324	$0	13,296	D
Restricted Stock Units	$0	10/01/2026		M			1,701	⁽⁶⁾	⁽³⁾	Common Stock	1,701	$0	10,202	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.

5. This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

6. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Darya Chudova	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR